Matsuda L., et al. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/2165569/ [accessed 15 August 2021].
Pertwee, R. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology [online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219532/ [accessed 15 August 2021].
Bergamaschi, M., et al. (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology [online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079847/ [accessed 15 August 2021].
Hudson, R, et al. (2019). Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation. The Journal of Neuroscience [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/31570536/ [accessed 19 August 2021].
MacCallum, C., Russo, E. (2018). Practical Considerations in Medical Cannabis Administration and Dosing. European Journal of Internal Medicine [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/29307505/ [accessed 19 August 2021].
Healthcare Professionals Portal
Access a range of educational resources and detailed product information developed for prescribers and pharmacists.
Kind Medical acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.